Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ivonescimab in Endometrial and Cervical Cancers
NCT06925724Phase 2Recruiting
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Apr 2025
- Primary completion
- Apr 2027
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label trial of ivonescimab in endometrial cancer (EC) and Cervical Cancer (CC) (2 arms), sponsored by Memorial Sloan Kettering Cancer Center. Primary endpoint: Overall Response Rate at 27 weeks. Started Apr 2025; status: recruiting.
02
Drugs
ivonescimab
03
Conditions
endometrial cancer (EC)Cervical Cancer (CC)
Beyond the preview
Go deeper on NCT06925724.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06925724.